This observation was also supported by the TCGA dataset, which showed that newly diagnosed primary GBM patients with both RPS11 and RPS20 overexpression exhibited a 43% increase in the hazard of death when compared to 19% and 25% increases for RPS11 and RPS20 individually. This evidence concerns the gene RPS11 and glioblastoma.